These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3584763)

  • 41. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
    Nunzi E; Iorio AM; Camilloni B
    Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season.
    King JP; McLean HQ; Meece JK; Levine MZ; Spencer SM; Flannery B; Belongia EA
    Vaccine; 2018 Feb; 36(9):1214-1219. PubMed ID: 29395525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine.
    Muszkat M; Yehuda AB; Schein MH; Friedlander Y; Naveh P; Greenbaum E; Schlesinger M; Levy R; Zakay-Rones Z; Friedman G
    J Med Virol; 2000 May; 61(1):100-6. PubMed ID: 10745240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults.
    van den Berg SPH; Wong A; Hendriks M; Jacobi RHJ; van Baarle D; van Beek J
    Front Immunol; 2018; 9():82. PubMed ID: 29434600
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
    Taylor DN; Treanor JJ; Strout C; Johnson C; Fitzgerald T; Kavita U; Ozer K; Tussey L; Shaw A
    Vaccine; 2011 Jul; 29(31):4897-902. PubMed ID: 21596084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevaccination antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population.
    Matsushita M; Takeuchi S; Kumagai N; Uehara Y; Matsushita C; Arise K; Seo H; Awatani T
    Vaccine; 2012 Feb; 30(6):1101-7. PubMed ID: 22178518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
    N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Time to peak serum antibody response to influenza vaccine in the elderly.
    Gross PA; Russo C; Teplitzky M; Dran S; Cataruozolo P; Munk G
    Clin Diagn Lab Immunol; 1996 May; 3(3):361-2. PubMed ID: 8705685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.
    Samson SI; Leventhal PS; Salamand C; Meng Y; Seet BT; Landolfi V; Greenberg D; Hollingsworth R
    Expert Rev Vaccines; 2019 Mar; 18(3):295-308. PubMed ID: 30689467
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
    Webster A; Boyce M; Edmundson S; Miller I
    Clin Pharmacokinet; 1999; 36 Suppl 1():51-8. PubMed ID: 10429840
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
    Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
    J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patients.
    Ramanathan RK; Potter DM; Belani CP; Jacobs SA; Gravenstein S; Lim F; Kim H; Savona S; Evans T; Buchbarker D; Simon MB; Depee JK; Trump DL
    J Clin Oncol; 2002 Nov; 20(21):4313-8. PubMed ID: 12409329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma.
    Brydak LB; Machała M; Centkowski P; Warzocha K; Biliński P
    Vaccine; 2006 Nov; 24(44-46):6620-3. PubMed ID: 16870313
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
    Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.